Single-pass albumin dialysis as treatment of acute on chronic liver failure during COVID-19 pneumonia. report of one case
No Thumbnail Available
Date
2022-11
Profesor/a GuÃa
Facultad/escuela
Idioma
es
Journal Title
Journal ISSN
Volume Title
Publisher
Sociedad Medica de Santiago
Nombre de Curso
item.page.dc.rights
CC BY 4.0 DEED
Attribution 4.0 International
item.page.dc.rights
https://creativecommons.org/licenses/by/4.0/deed.en
Abstract
Liver transplantation is the only effective therapy to reduce the high mortality associated with acute liver failure and acute on chronic liver failure (ACLF). Single-pass albumin dialysis (SPAD) is an extracorporeal supportive therapy used as a bridge to liver transplantation or regeneration. We report a 44-year-old man with alcoholic cirrhosis admitted for critical COVID-19 pneumonia that evolves with ACLF. SPAD technique was performed completing six sessions, with a reduction of bilirubin and ammonia levels. He evolved with severe respiratory failure and refractory septic shock, dying. SPAD is a safe and efficient technique aimed to eliminate liver toxins, preventing multiorgan damage interrupting the process known as the "autointoxication hypothesis". It is easy to implement in any critical patient unit and has lower costs than other extracorporeal liver support therapies. © 2022 Sociedad Medica de Santiago. All rights reserved.
item.page.dc.description
Indexación: Scopus.
Keywords
Acute, Acute-On-Chronic Liver Failure, Artificial, Covid-19, Liver, Liver Failure, Adult, Albumins, Humans, Liver Transplantation, Male, Renal Dialysis
Citation
Revista Medica de Chile, Volume 150, Issue 11, Pages 1540 - 1544, November 2022
DOI
10.4067/S0034-98872022001101540